Concord Biotech Limited share price
NSE: CONCORDBIO · ISIN INE338H01029
Key numbers
- Market cap
- ₹ 15,207 Cr
- Current price
- ₹ 1,453.60
- 52-week high / low
- ₹ 1,668 / 987
- Stock P/E
- 52.8
- Book value
- ₹ 192.8
- Dividend yield
- 0.52%
- ROCE
- 18.0%
- ROE
- 13.6%
- Debt to equity
- 0.00
- Sales growth (3 yrs)
- 8.0%
- Profit growth (3 yrs)
- 2.8%
- 1-year return
- -10.8%
About Concord Biotech Limited
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 204 | 247 | 278 | 326 | 257 |
| Operating profit | 61 | 88 | 99 | 119 | 82 |
| Net profit | 44 | 63 | 64 | 89 | 58 |
| EPS (₹) | 4.21 | 6.03 | 6.08 | 8.46 | 8.46 |
Concall summary (2026-08-07)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- We are pleased to report a strong start to FY27 with Q1 FY27 revenues of INR257 crores, reflecting a healthy 26% year-on-year growth.
- Revenue for Q1 FY27 stood at INR257 crores compared to INR204 crores in the Q1 FY26, a growth of 26.2%.
Growth & demand
- Our export business remained a key growth driver with export revenues increasing 46% year - on-year in Q1 FY27.
- Our product pipeline remains robust with plans to launch 2 to 3 new products annually.
Margins & costs
- Gross margins for the quarter stood at 78.9%, an increase of 100 bps Y-o-Y.
- EBITDA for Q1 FY27 stood at INR82 crores, a growth of 34% and EBI TDA margins stood at 32%, an increase of 190 bps year-on-year.
Capex & expansion
- Lastly, we are a zero debt comp any and with cash and cash equivalent of more than INR442 crores as on 30th June, our capex for the quarter stood at around INR9.5 crores.
- Concord Biotech Limited August 03, 2026 And on the API front, as you would see that the capacity utilization for Unit 3 has been close to around 50%, 55%.
Balance sheet & cash
- Whenever the opportunity exists that are not addressable through APIs, we leverage our formulation capabilities with the corresponding API requirements being sourced internally.
- No, that's very thoughtful and we know that ours is a net cash balance sheet.
Peers in Biotechnology
Data for information only, not investment advice. Prices end of day.